Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

Proven Durability: Groundbreaking Gene Therapy Persistence Data

Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer

A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…